Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tau PET Imaging in Atypical Dementias
NCT03283449Phase 1Completed
- Sponsor
- University of Chicago
- Start
- Feb 2016
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of flortaucipir in primary progressive aphasia (PPA), sponsored by University of Chicago. Primary endpoint: Tau levels in PPA participants at 2 years. Started Feb 2016; status: completed.
02
Drugs
flortaucipir
03
Conditions
primary progressive aphasia (PPA)
Beyond the preview
Go deeper on NCT03283449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283449.